A Study of CSTI-500 in Patients With Prader-Willi Syndrome

Summary

This is a proof-of-concept, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CSTI-500 in participants with genetically confirmed Prader-Willi Syndrome (PWS) who are 13 to 50 years of age. Participants will receive increasing doses of CSTI-500, and blood levels will be measured to guide individualized dosing.

Timeline

Start

2026-05

Primary completion

2027-06

Completion

2027-06

Drugs

Indications